Home / Knowledge Centre /

NGS Panels – From Patient Selection to CDx

NGS panels are a powerful tool for parallel assessment of genomic integrity and expression across multiple targets. This facilitates biomarker discovery in early phase clinical trials and also subsequent development of CDx assays with potential utility across multiple drug targets.

In this webinar, Dr Cheryl McFarlane, Operations Manager at Almac Diagnostic Services will summarise the main considerations of development and analytical validation of such panels and describe our experience identifying important technical and regulatory challenges.

Topics covered include:

  • Use of NGS panels for patient selection
  • Biomarker Discovery pathway in early phase trials
  • A customised CDx Development approach
  • Regulatory challenges and solutions
View Resource
Almac Logo

Diagnostic Services

Your global partner for biomarker discovery, development & commercialisation.

Genomic Services

We offer a range of genomics platform and chemistry options, alongside expert data sciences support and a full sample management service.

Clinical Trial Assays

Comprehensive development, validation & delivery service for research and clinical use assays from our global clinical laboratories in USA, Europe and APAC.

Companion Diagnostics

A collaborative Companion Diagnostic partnership approach with a deep understanding of client needs. We offer CDx development, manufacture & commercialisation services.

Learn More

Please complete this form to view the Webinar

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies